Medical apparatus carrying gene and/or medicament and preparation method thereof

Abstract

The invention relates to a medical apparatus carrying gene and / or medicament and a preparation method thereof. The medical apparatus employs the electrostatic adhesion and / or micropore adhesion principle, the surface of the medical apparatus body is directly coated and / or fixed with active medicament and / or therapeutic genes, the invention has the advantages that various therapeutic genes and medicament are compounded on the same platform and the advantages of plural therapeutic genes and medicament are combined, thus radically solving the problems of restenosis and endothelialization delay. The preparation method is simple, the fixing effects of gene and medicament are good, the introduction of matrix carrier loaded with medicament and genes can be saved, the reaction hazard of restenosis and phlegmonosis caused by implantation can be reduced, and the cure effect is better than that of the current implanted medical apparatus.

Description

technical field [0001] The invention relates to the field of medical devices, in particular to a medical device carrying genes and / or drugs and a preparation method thereof. Background technique [0002] In 1987, since Sigwart et al. used intravascular metal stents for coronary arteries for the first time, it has provided a good way for the treatment of vascular occlusion diseases. However, in-stent restenosis has always been the main reason affecting the efficacy of percutaneous coronary intervention (PCI). With the listing of Johnson & Johnson's Cypher rapamycin drug stent in 2004 and Boston Scientific's Taxus paclitaxel drug stent in 2005, drug-eluting stents have reduced the in-stent restenosis rate from 30% in the bare metal stent era to less than 10%. [0003] However, with the in-depth study of drug stents, the continuous expansion of the scope of application, and the gradual increase in the number of accumulated cases, people should become more rational in their use...

AI Technical Summary

Problems solved by technology

[0008] At present, there are several problems in all the animal experiments of loading the therapeutic gene on the stent: (1) How to firmly adsorb the therapeutic gene on the surface of the stent and transport it to the The lesion site becomes a key obstacle to the clinical application of this method

In this way, the binding force between the polymer carrier coating or the protein coating itself and the metal substrate is easy to separate from the metal substrate under the impact of high-speed blood flow, especially those coatings such as collagen and polylysine that are very soluble in water. In this way, the therapeutic genes loaded on the coating will be lost in large quantities with the impact of blood flow, and the amount of genes reaching the target lesion is limited; at the same time, the introduction of polymer carriers or protein coatings as foreign bodies in the body will cause stress and immunity of the matrix. Reactions, especially immune rejection from the protein coating, can greatly weaken the effect of gene therapy

(2) All the single gene studies that have been loaded on the stent can only reduce the incidence of intravascular restenosis or thrombosis to a certain extent, and there is no unique gene that can target endothelial cells and smooth muscle cells at the same time. Inhibits the proliferation of smooth muscle cells while repairing the endothelium

In addition, loading genes onto vascular stents by adsorption methods has the disadvantage that the combination of genes and stents is not firm and is easily washed away by blood flow.

Images